Clinical Trials
49 trialsPolarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
Taipei Medical University Shuang Ho Hospital
Photodynamic Therapy-Induced Immune Modulation: Part III
Wright State University
Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery
Case Comprehensive Cancer Center
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Pfizer
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
CHIP
Pfizer
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
Case Comprehensive Cancer Center
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
University of California, Irvine
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
SWOG Cancer Research Network
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
National Institutes of Health Clinical Center (CC)
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
University of Chicago
Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer
Stanford University
ADAPT
University of Washington
Pre-Prostatectomy Celecoxib or Placebo
OHSU Knight Cancer Institute
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Alliance for Clinical Trials in Oncology
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
Alliance for Clinical Trials in Oncology
Preemptive Analgesia Following Uterine Artery Embolization
Northwestern University
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Indiana University
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
M.D. Anderson Cancer Center
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
New Mexico Cancer Research Alliance
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
HaEmek Medical Center, Israel
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
HaEmek Medical Center, Israel
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
HaEmek Medical Center, Israel
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study of High-Risk Oral Cavity Cancer
National Health Research Institutes, Taiwan
A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
University of Southern California
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Celecoxib in Treating Patients With Early-Stage Rectal Cancer
Vanderbilt-Ingram Cancer Center
Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer
NSABP Foundation Inc
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
M.D. Anderson Cancer Center
Celebrex (Celecoxib) Treatment of Laryngeal Papilloma
Boston University
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
UNC Lineberger Comprehensive Cancer Center
A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers
Montefiore Medical Center
Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
University of Pittsburgh
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Pfizer